Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions
Launched by SIMMARON RESEARCH INC. · Feb 12, 2024
Trial Information
Current as of July 24, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of ME/CFS that meets the Institute of Medicine (IOM) criteria
- • Diagnosis of Long-COVID (PASC clinical criteria)
- Exclusion Criteria:
- • No diagnosis of ME/CFS or Long-COVID
About Simmaron Research Inc.
Simmaron Research Inc. is a pioneering clinical research organization dedicated to advancing medical science through the management and execution of clinical trials. With a focus on innovative therapies and patient-centered approaches, Simmaron collaborates with pharmaceutical and biotechnology companies to facilitate the development of new treatments across various therapeutic areas. Their experienced team employs rigorous methodologies and adheres to the highest ethical standards to ensure the integrity and reliability of clinical data. By fostering partnerships and leveraging cutting-edge technology, Simmaron Research Inc. aims to accelerate the journey from research to market, ultimately enhancing patient outcomes and contributing to the advancement of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Incline Village, Nevada, United States
Salt Lake City, Utah, United States
Palo Alto, California, United States
Seattle, Washington, United States
Patients applied
Trial Officials
Gunnar Gottschalk, PhD
Principal Investigator
Simmaron Research Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported